Table 2.

Characteristics of included 11 randomized controlled trials (A and B).

(A)
Author	Number of cases		Gender proportion (male/female)	Age		Interventions		Outcomes
	Control group	Experimental group		Control group	Experimental group
						Control group	Experimental group
Su N 2021[6]	30	30	37/23	62.05 ± 6.29	61.43 ± 6.45	Cisplatin 40–50 mg/time, d1, d4	Endostar 60 mg/time, d1, d4 Cisplatin 40–50 mg/time, d2, d5	①③④
								⑤ ⑥
Yang Y 2013[7]	21	21	27/15	37–80		Cisplatin 40 mg once a week	Endostar 30 mg twice a week Cisplatin 40 mg once a week	①②③
								④⑤⑥
Liu YF 2018[8]	34	34	38/30	65.55 ± 5.28	63.19 ± 4.73	Cisplatin 60 mg + 0.9% sodium chloride solution 20 mg, twice a week	Cisplatin 60 mg + Endostar 60 mg + 0.9% sodium chloride solution 20 mg, twice a week	① ②
								③ ④
Chen J 2014[9]	30	30	44/16	55.6 ± 4.5	54.3 ± 5.6	Cisplatin 40 mg twice a week	Cisplatin 40 mg + Endostar 45 mg twice a week	①③④
								⑤ ⑥
Tu JR 2014[10]	45	45	48/42	47.5 ± 10.5	46.5 ± 11.5	Cisplatin 40 mg/m2 + 0.9% sodium chloride solution 40 mL twice a week for 3 wk	Endostar 45 mg, concurrently injected with cisplatin 40 mg/m2 + 0.9% sodium chloride solution 40 mL, twice a week for 3 consecutive weeks	①②③
								④ ⑤
Lu XD 2017[11]	31	31	35/27	45.7 ± 11.3	46.3 ± 10.6	Inject cisplatin 40 mg/m2 + 0.9% sodium chloride solution 40 mL, twice a week for 3 consecutive weeks	Recombinant human Endostarin 45 mg + cisplatin 40 mg/m2 + 0.9% sodium chloride solution 40 mL, 2 times a week for 3 consecutive weeks	①②③
								④ ⑤
Xu XZ 2021[12]	75	75	79/71	63.87 ± 5.38	63.65 ± 5.11	Cisplatin injection 10 mg: 2 mL intrapleural injection, once a week for 3 wk	Cisplatin injection 10 mg: 2 mL intrapleural injection, once a week, for 3 weeks, recombinant human Endostarin injection 15 mg: 3 mL intrapleural infusion, 45 mg each time, once a week, 3 weeks of continuous use	①③⑤
Wang R 2018[13]	30	30	35/25	60.54 ± 5.65	61.28 ± 6.32	Cisplatin 40 mg/m2 twice a week for 3 wk	Cisplatin 40 mg/m2, 2 times/wk, for 3 wk Recombinant human Endostarin 45 mg/time, 2 times/wk, for 3 wk	①③⑤
Shen Q 2012[14]	40	40	42/38	37–79		Cisplatin 40 mg once a week	Cisplatin 40 mg once a week + Endostar 30 mg twice a week	①②③
								④⑤⑥
Liu HX 2018[15]	26	26	23/29	39–75	41–75	Cisplatin 30 mg + 29mL 0.9% sodium chloride solution, twice a week, for 2 to 3 weeks, once a week after the pleural effusion is stable	Endostar 45mg + cisplatin 30 mg + 20 mL 0.9% sodium chloride solution, twice a week, for 2 to 3 wk, and once a week after the pleural effusion stabilizes	①③
								④⑤
Chen RL 2016[16]	45	45	53/37	60.8 ± 7.5	60.6 ± 7.2	Cisplatin injection 40 mg/m2 + 0.9% sodium chloride solution 40, 2 times/wk	Cisplatin injection 40 mg/m2 + 0.9% sodium chloride solution 40, 2 times/wk; Recombinant human Endostarin injection 45 mg, 2 times/wk	①②③
								④ ⑥
(B)
Author	Random method			Allocation hidden	Blind	Selective reporting of research findings	Integrity of the resulting data	Other sources of bias
Su N 2021[6]	Random number table			Unclear	Unblinded	Not	Not	Not
Yang Y 2013[7]	Random number table			Unclear	Unblinded	Not	Not	Not
Liu YF 2018[8]	Unclear			Unclear	Unclear	Not	Not	Not
Chen J 2014[9]	Unclear			Unclear	Unclear	Not	Not	Not
Tu JR 2014[10]	Random number table			Unclear	Unblinded	Not	Not	Not
Lu XD 2017[11]	Random number table			Unclear	Unblinded	Not	Not	Not
Xu XZ 2021[12]	Random number table			Unclear	Unblinded	Not	Not	Not
Wang R 2018[13]	Random number table			Unclear	Unclear	Not	Not	Not
Shen Q 2012[14]	Random number table			Unclear	Unblinded	Not	Not	Not
Liu HX 2018[15]	Random number table			Unclear	Unblinded	Not	Not	Not
Chen RL 2016[16]	Unclear			Unclear	Unblinded	Not	Not	Not

① = the overall response rate, ② = quality of life improvement rate, ③ = incidence of gastrointestinal reactions, ④ = the incidence of leukopenia, ⑤ = the incidence of thrombocytopenia, ⑥ = the incidence of hypodynamia.